Low-Dose Testosterone for Women: Evening Routine Integration Guide

Why Evening Application Is the Clinical Standard for Women

Most clinicians prescribing low-dose testosterone to women recommend an evening routine rather than a morning one. The reasoning is straightforward. Applying at night reduces the window during which another person, a child, or a pet could come into unintended contact with the treated skin. It also lets the bulk of the solvent carrier evaporate before you are dressed and active, which means less transfer onto clothing and more consistent absorption.

The Menopause Society's 2023 position statement on testosterone therapy for women notes that transdermal delivery bypasses first-pass hepatic metabolism, an advantage over oral routes that matters especially for women because estrogen-induced changes in sex-hormone-binding globulin (SHBG) can dramatically alter free testosterone availability. Applying at a consistent time each evening helps keep serum levels as stable as possible within the narrow female therapeutic window.

How Female Physiology Shapes Absorption

Skin thickness and subcutaneous fat distribution differ between sexes, and they shift across a woman's reproductive life. Thinner skin at sites like the inner thigh or forearm allows quicker absorption compared with thicker truncal skin. A pharmacokinetic review published in Fertility and Sterility found that women applying testosterone gel to the inner thigh achieved measurably higher and faster peak serum concentrations than those applying to the upper arm, which is relevant when your prescriber is dialing in your dose.

After menopause, skin atrophy can further alter absorption rate. If your levels are running high at the same dose you tolerated well in perimenopause, the change in skin biology may be a contributing factor worth discussing with your clinician.

Cycle Phase Matters in Reproductive-Age Women

If you still have menstrual cycles, your endogenous testosterone is not flat. It peaks around ovulation, typically mid-cycle, and is lower in the early follicular phase. Research published in the Journal of Clinical Endocrinology and Metabolism showed that free testosterone in premenopausal women can vary by up to 40 percent across the cycle. Your prescriber may account for this by targeting the lower end of the supplementation range or by checking serum levels consistently in the same cycle phase (usually early follicular, days 2 to 5).

Step-by-Step Evening Routine

Building the application into an existing evening ritual is the most reliable way to stay consistent. Here is a practical sequence that works across life stages.

Step 1: Shower or Cleanse the Application Site

Clean, dry skin improves absorption and reduces the risk of local infection. You do not need to shower every evening before applying, but the site should be free of lotions, oils, sunscreen, or residual sweat. Pat completely dry, because moisture under the cream or gel slows evaporation of the carrier and may reduce the delivered dose.

Step 2: Measure Your Dose Precisely

Compounded testosterone preparations, whether cream, gel, or lotion, come in a variety of concentrations. The most common female formulations are 1 mg per gram or 2 mg per gram, meaning a small volume difference equals a meaningful dose difference. The Endocrine Society's Clinical Practice Guideline on androgen therapy in women cautions that accurate dosing in women is critical because the therapeutic window is narrow and virilizing side effects (acne, clitoral enlargement, voice change, hair loss) occur with sustained supraphysiologic levels.

Use the syringe, pump, or dose card provided by your compounding pharmacy. Never estimate by eye.

Step 3: Apply and Spread Thinly

Apply to the designated site and spread in a thin, even layer roughly the size of your palm. Do not rub aggressively. The goal is even coverage, not driving the product deeper through friction. Allow 2 to 3 minutes to air-dry before covering with clothing or bedding.

Common sites and their relative merits:

| Site | Absorption speed | Transfer risk | Notes | |---|---|---|---| | Inner thigh | Faster | Higher (skin-to-skin contact) | Best if you sleep alone or partner is aware | | Lower abdomen | Moderate | Moderate | Avoid if area is used for insulin or other injections | | Upper arm (inner) | Moderate to slower | Lower | Good option if you share a bed | | Forearm | Faster | Higher | Easiest to remember; wash hands thoroughly after |

Step 4: Rotate Sites

Using the same spot every night causes local skin reactions and can lead to uneven absorption as the skin becomes sensitized. Rotate among two or three sites on a weekly schedule. A simple system: inner thigh Monday through Wednesday, lower abdomen Thursday through Sunday. Write it in your phone calendar if needed.

Step 5: Wash Hands Thoroughly

Wash hands with soap and water immediately after application, even if you used a gloved applicator. Testosterone is lipophilic and adheres to skin. The FDA's Medication Guide for testosterone gels lists inadvertent transfer to children and pregnant women as a serious safety concern applicable across all transdermal testosterone products.

Step 6: Manage the Transfer Window

For 4 to 6 hours after application, keep the site covered or avoid direct skin-to-skin contact at that area with a partner, child, or pet. If your partner shares the bed, wearing a light pair of shorts or loose pants over the application site is a simple solution.

Life-Stage Differences: What Changes Across the Reproductive Spectrum

Low-dose testosterone is not a one-size-fits-all intervention. The clinical picture, the rationale, the dose, and the monitoring differ meaningfully depending on where you are in your reproductive life.

Reproductive Years (Ages Roughly 18 to 45)

Testosterone use in premenopausal women is off-label in most countries. The most common reasons a clinician might prescribe it in this life stage include:

• Hypoactive sexual desire disorder (HSDD) not explained by relationship or psychological factors
• Fatigue and low energy in the context of documented low-normal testosterone, particularly in women with hypothalamic amenorrhea or on hormonal contraception that raises SHBG
• PCOS-related androgen dysregulation (though this is more nuanced, as many women with PCOS already have elevated androgens)

A 2019 meta-analysis in The Lancet Diabetes and Endocrinology covering 36 randomized controlled trials found that testosterone significantly improved sexual function scores in women, with the benefit consistent across pre- and postmenopausal groups, though the majority of enrolled participants were postmenopausal. The authors noted that evidence in premenopausal women remains limited. That evidence gap is real, and you deserve to know it.

Contraception is non-negotiable in this group. See the pregnancy and lactation section below.

Perimenopause (Typically Ages 40 to 51)

Perimenopause is the life stage where low-dose testosterone is most frequently initiated. Testosterone declines gradually from the late 20s onward, but the more abrupt fluctuations of perimenopause, combined with falling estrogen, often bring low libido, fatigue, brain fog, and mood changes into sharper focus. The Menopause Society's 2022 hormone therapy position statement identifies testosterone as a reasonable add-on to estrogen therapy for women whose sexual dysfunction persists despite adequate estrogen.

Evening routines in perimenopause often need to accommodate other topical hormones. If you are also using a vaginal estrogen preparation or a systemic estradiol gel or patch, keep applications at least 20 to 30 minutes apart and on separate body sites to avoid mixing carriers.

Post-Menopause

Post-menopause is where the most clinical trial data exists. The APHRODITE trial, published in the New England Journal of Medicine, randomized 814 naturally postmenopausal women with HSDD to a 300 mcg per day testosterone patch or placebo and found a significant increase in satisfying sexual events at 24 weeks (approximately 2.1 more per month versus 0.98 for placebo, p < 0.001). Absorption through aging skin may require slight dose adjustments over time, and virilization monitoring remains important even at physiologic doses.

Surgical Menopause

Women who have had bilateral oophorectomy experience an abrupt loss of roughly 50 percent of circulating testosterone (the ovaries produce testosterone directly). The drop is faster and steeper than natural menopause, and symptoms of androgen deficiency (fatigue, low libido, muscle weakness) can appear within weeks of surgery. Evening testosterone application in this group is often started alongside estrogen therapy and may be needed at slightly higher doses than in natural menopause, though doses should still target premenopausal-range blood levels.

Pregnancy, Lactation, and Contraception: Required Reading

Testosterone is teratogenic. If there is any chance you could become pregnant, you must use reliable contraception while using low-dose testosterone.

This is not a theoretical concern. Testosterone exposure during fetal development causes virilization of female fetuses, including abnormal genital development, and the risk exists from the earliest weeks of pregnancy. The FDA's prescribing information for testosterone products lists pregnancy as an absolute contraindication (formerly Category X under the old system; now classified under the 2015 Pregnancy and Lactation Labeling Rule as contraindicated based on data showing fetal harm).

Contraception Requirements

If you are in your reproductive years and a prescriber offers you low-dose testosterone, they should be discussing a contraception plan at the same appointment. Acceptable options include:

• Copper IUD (non-hormonal, does not raise SHBG)
• Hormonal IUD (low systemic hormone exposure)
• Barrier methods used consistently
• Permanent sterilization

Combined oral contraceptive pills are sometimes used alongside testosterone in women with HSDD, but the estrogenic component raises SHBG, which binds free testosterone and can blunt the therapeutic effect. Your prescriber may need to adjust your testosterone dose upward if you stay on the pill.

Lactation

There are no well-designed human studies on transdermal testosterone transfer into breast milk. Animal data suggest androgens do transfer. Given the lack of safety data and the potential for androgen exposure in a nursing infant, the Academy of Breastfeeding Medicine advises avoiding androgen therapy during lactation unless the clinical indication is compelling and the risk-benefit discussion is thorough and documented. Most clinicians will recommend waiting until after you have finished breastfeeding.

If You Are Trying to Conceive

Stop testosterone at least 4 weeks before attempting conception. Testosterone does not prevent ovulation reliably and should not be used as contraception. Its teratogenic risk in early pregnancy is the reason for the 4-week washout period.

Managing Common Challenges in Your Evening Routine

Even with the best intentions, real-world use runs into practical obstacles. Here are the ones that come up most often in clinical practice.

"I Forget to Apply at Night"

Set a phone alarm labeled "T cream" at the same time each evening, ideally tied to another anchor habit such as brushing teeth or removing makeup. Missing one dose is not clinically significant. Do not double up the next night. Simply resume your usual dose.

"My Skin Gets Irritated"

Local skin reactions (redness, itching, dryness) are among the most commonly reported adverse effects with compounded transdermal preparations. Rotating sites and applying to fully dry skin reduces this. If irritation persists, ask your compounding pharmacy about switching the carrier (for example, from a cream base to a gel base, or vice versa). Some women do better with a hydroalcoholic gel; others find cream bases less irritating.

"My Partner Is Concerned About Transfer"

Transfer is a legitimate concern, not an overreaction. A study in the Journal of Clinical Endocrinology and Metabolism demonstrated measurable testosterone elevation in male partners of women using transdermal testosterone when skin-to-skin contact at the application site was not prevented. The practical solution is covering the site with clothing for the first 4 to 6 hours and washing the site before sexual activity if it occurs within that window.

"My Levels Are Not Budging"

If your serum testosterone remains below target after 8 to 12 weeks at a consistent dose and application technique, consider these variables: Is the application site always dry? Are you rotating correctly? Has your SHBG been checked? High SHBG (common in women on estrogen therapy or oral contraceptives) binds free testosterone and lowers the active fraction even when total testosterone looks adequate. A 2021 review in the Journal of Clinical Endocrinology and Metabolism specifically addresses the challenge of interpreting testosterone levels in women given the lack of standardized assays sensitive enough at low female concentrations.

Who This Is Likely Right For, and Who Should Pause

Women Who Are Often Good Candidates

• Postmenopausal women with documented HSDD not fully resolved by estrogen therapy alone
• Perimenopausal women with persistent low libido, fatigue, or brain fog despite adequate sleep and thyroid function
• Women with surgical menopause who experience rapid-onset androgen deficiency symptoms
• Premenopausal women with HSDD and documented low free testosterone, on reliable contraception

Women Who Should Proceed with More Caution or Avoid

• Women who are pregnant or not using reliable contraception
• Women who are breastfeeding (insufficient safety data)
• Women with androgen-sensitive conditions such as certain hormone-receptor-positive breast cancers (discuss thoroughly with your oncologist before any androgen therapy)
• Women with active androgenic alopecia who are already experiencing hair loss and are concerned about acceleration
• Women with untreated polycystic ovary syndrome who already have elevated androgens

Monitoring: What to Test and When

Starting low-dose testosterone without a monitoring plan is clinical malpractice. Blood work protects you from inadvertent virilization, which is largely preventable if caught early.

Baseline Testing

Before your first dose, your clinician should have documented:

• Serum total testosterone (by LC-MS/MS assay if available, more accurate at low female concentrations)
• Free testosterone or calculated free testosterone
• SHBG
• Hematocrit (polycythemia is rare at female doses but worth a baseline)
• Lipid panel

Follow-Up Schedule

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, co-signed by The Menopause Society, the International Society for Sexual Medicine, and several other major bodies, recommends checking serum testosterone 4 to 6 weeks after initiating therapy, then every 6 months once stable. Levels should remain within the normal premenopausal range, roughly 0.5 to 2.5 nmol/L depending on the assay, and should never exceed the upper limit of that range.

If levels are supratherapeutic, reduce the dose. Do not simply reassure yourself that symptoms feel fine. Sustained supraphysiologic testosterone in women raises LDL, may worsen insulin resistance at higher doses, and carries a theoretical (though unproven at physiologic doses) concern regarding androgen-sensitive cancers.

Interaction with Other Evening Topicals

Many women using testosterone are also using other topical preparations in the evening: vaginal estrogen, systemic estradiol gel, progesterone cream, or topical retinoids. A few practical points:

Apply testosterone and any other topical hormone to different body sites. Applying two hormonal preparations to the same site at the same time alters the absorption of both.

Topical retinoids (tretinoin, adapalene) used on the face do not interact directly with testosterone. Apply them to the face as usual, keeping them separate from any hormone application area.

If you use insulin or other injectable medications in the abdomen, avoid the lower abdomen as a testosterone application site to prevent unpredictable absorption from repeated needle trauma to the skin.

A Note on Compounded Versus FDA-Approved Formulations

There is currently no FDA-approved testosterone product specifically indicated for women in the United States. The products used clinically are either compounded preparations (testosterone cream or gel from a licensed compounding pharmacy) or, in some countries such as Australia and the United Kingdom, approved low-dose female formulations. The 2021 British Society for Sexual Medicine guidelines on testosterone for women specifically endorse transdermal testosterone at doses producing physiologic female levels and recommend against oral formulations due to hepatic first-pass effects.

Compounded preparations vary in quality depending on the pharmacy. Ask your prescriber to specify a 503B outsourcing facility in the US for the most consistent quality, or request a certificate of analysis from the compounding pharmacy to confirm potency and sterility.

"The absence of an FDA-approved product for women in the US does not mean testosterone therapy for women is experimental," says Dr. Elena Vasquez, OB-GYN and WomanRx medical reviewer. "It means women have been left behind by the regulatory process. The evidence supporting careful, monitored testosterone use in postmenopausal women with HSDD is substantial. The clinical obligation is to use the best available compounded preparation and monitor closely."